UPDATE 1-Auxilium posts narrower-than-expected Q4 loss
* Q4 loss $0.25/shr vs est loss $0.31/shr
* Q4 revenue up 38 pct at $48 mln
* Says US sales of testosterone drug strong
* Sees '10 revenue of $185-$195 mln from Testim
Feb 17 (Reuters) - Auxilium Pharmaceuticals Inc (AUXL.O) posted a narrower-than-expected quarterly loss, helped by strong sales of Testim, its gel to treat low testosterone, in the United States.
For the latest fourth quarter, the company reported a net loss of $11.9 million, or 25 cents a share, compared with a loss of $12.1 million, or 29 cents a share, a year earlier.
Analysts on average had expected a loss of 31 cents a share, excluding special items, on revenue of $44.3 million, according to Thomson Reuters I/B/E/S.
Revenue rose 38 percent to $48.0 million.
U.S. sales of Testim rose to $42.3 million from $34.0 million in the year-ago quarter.
For 2010, the company expects Testim revenue of $185 million to $195 million.
The company also said it has priced its drug Xiaflex to distributors at $3,250 per vial.
Earlier this month, U.S. regulators had approved Xiaflex for treating a progressive hand disease known as Dupuytren's contracture, and the company plans a launch for late March. [ID:nN02119214]
Shares of the company were up about 1 percent in trading before the bell. They closed at $31.70 Tuesday on Nasdaq. (Reporting by Shailesh Kuber in Bangalore; Editing by Gopakumar Warrier)